How would you manage a patient with synchronous breast and ovarian cancer, s/p neoadjuvant chemotherapy and surgery for ER+/HER2- breast cancer and found to have an ER+ ovarian cancer nodal metastases at TAH/BSO?

Topics: Breast Cancer • Gynecologic Cancers • Medical Oncology • NCI-CCC Tumor Board Question • Moffitt Cancer Center

RP node with treatment related changes and surgical specimen from TAH/BSO no other foci of malignancy found.

Answer from: Medical Oncologist at Academic Institution

I usually treat my triple negative breast cancer patients (whether or not there's a deleterious mutation in the homologous recombination repair pathway, e.g. BRCA1 or BRCA2) with neoadjuvant docetaxel + carboplatin. The addition of carboplatin to taxane-based neoadjuvant chemotherapy regimens was ev...

Related Questions